Our goal is to study the molecular events related to heavy chain class switching in a murine B cell lymphoma, BCL1. In the first grant the primary focus was to obtain inducible versions of BCL1 that displayed various developmental phenotypes and to study the DNA rearrangements accompanying ligand-induced differentiation. Two major results from these studies have provided the basis for the present proposal: First, BCL1 can undergo differentiation from IgM+IgD expression to stable IgM+IgG1, allelically excluded double-production without DNA rearrangement of the heavy chain constant region genes. Second, certain T cell-derived supernatants contain an activity (BCDFGamma) that induces specific expression of IgG1 by interaction with a cell surface receptor, putatively identified by a monoclonal antibody. A primary objective, made possible by the unique BCL2 line, is to determine the detailed molecular mechanism for dual Mu and Gamma1 isotype production. Using BCL2 clones which express different ratios of Mu to Gamma1 we will determine the point at which regulation of the relative isotype levels and their membrane and secreted forms is exerted. Dual IgM and IgG production may be an intermediate phenotype (e.g., memory cell) to terminal differentiation. Therefore we will attempt to induce BCL2 nonsecreting subclones to undergo further differentiation using BCDFGamma, its anti-receptor antibody and other ligands. To test the mechanism of BCDFGamma action, we will determine if receptor-positive BCL1 cells transfected with productively rearranged Gamma1 and Gamma3 vectors will undergo ligand induced differentiation. Finally, a study of the chromatin alterations in BCL1 is designed to test whether there is a molecular basis for the """"""""precommitted"""""""" switch to Gamma1 observed in these cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA031534-08
Application #
3169652
Study Section
Experimental Immunology Study Section (EI)
Project Start
1982-03-01
Project End
1991-02-28
Budget Start
1989-03-01
Budget End
1990-02-28
Support Year
8
Fiscal Year
1989
Total Cost
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Type
Overall Medical
DUNS #
City
Dallas
State
TX
Country
United States
Zip Code
75390
Warren, Junco S; Tracy, Christopher M; Miller, Mickey R et al. (2018) Histone methyltransferase Smyd1 regulates mitochondrial energetics in the heart. Proc Natl Acad Sci U S A 115:E7871-E7880
Nie, Hui; Rathbun, Gary; Tucker, Haley (2017) Smyd1C Mediates CD8 T Cell Death via Regulation of Bcl2-Mediated Restriction of outer Mitochondrial Membrane Integrity. J Cell Signal 2:
Rhee, Catherine; Edwards, Melissa; Dang, Christine et al. (2017) ARID3A is required for mammalian placenta development. Dev Biol 422:83-91
Rhee, Catherine; Kim, Jonghwan; Tucker, Haley O (2017) Transcriptional Regulation of the First Cell Fate Decision. J Dev Biol Regen Med 1:
Kim, Dongkyoon; Schmidt, Christian; Brown, Mark A et al. (2017) Competitive Promoter-Associated Matrix Attachment Region Binding of the Arid3a and Cux1 Transcription Factors. Diseases 5:
Li, Hanjun; Liu, Pei; Xu, Shuqin et al. (2017) FOXP1 controls mesenchymal stem cell commitment and senescence during skeletal aging. J Clin Invest 127:1241-1253
Dekker, Joseph D; Park, Daechan; Shaffer 3rd, Arthur L et al. (2016) Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1. Proc Natl Acad Sci U S A 113:E577-86
Li, Shanru; Morley, Michael; Lu, MinMin et al. (2016) Foxp transcription factors suppress a non-pulmonary gene expression program to permit proper lung development. Dev Biol 416:338-46
Woodworth, Mollie B; Greig, Luciano C; Liu, Kevin X et al. (2016) Ctip1 Regulates the Balance between Specification of Distinct Projection Neuron Subtypes in Deep Cortical Layers. Cell Rep 15:999-1012
Huang, Ching-Jung; Das, Utsab; Xie, Weijun et al. (2016) Altered stoichiometry and nuclear delocalization of NonO and PSF promote cellular senescence. Aging (Albany NY) 8:3356-3374

Showing the most recent 10 out of 54 publications